Trial Profile

Phase IIb trial of FV 100 in patients with herpes zoster infections

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valnivudine (Primary)
Indications Neuropathic pain; Postherpetic neuralgia
Focus Therapeutic Use
Sponsors Hepion Pharmaceuticals

Most Recent Events

09 Dec 2014 Status changed from planning to not yet recruiting, according to a ContraVir Pharmaceuticals media release.
08 Jul 2014 ContraVir Pharmaceuticals now plans to initiate this phase IIb trial. ContraVir Pharmaceuticals spin off of Synergy Pharmaceuticals and became an independent public company in January 2014.
08 Jul 2014 Planned initiation date changed from 1 Jun 2012 to 1 Oct 2014 according to a ContraVir Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com